Skip to main content

Table 3 Stepwise Logistic Regression Models Predicting Optimal SSE at 3, 12, and 24-Months Post the Dermatological Education Session

From: Short and long-term barriers and facilitators of skin self-examination among individuals diagnosed with melanoma

 

SSE at 3-months

 

SSE at 12 months

 

SSE at 24 months

 

Variable

Optimal (n = 85)

Not Optimal (n = 60)

Adj* OR [95% CI]

Optimal (n = 60)

Not Optimal (n = 70)

Adj* OR [95% CI]

Optimal (n = 34)

Not Optimal (n = 67)

Adj* OR [95% CI]

Sex, Female

36.0 (42.4)

35.0 (58.3)

0.33 [0.12, 0.93]

28.0 (46.7)

37.0 (52.9)

1.00 [0.40, 2.52]

18.0 (52.9)

35.0 (52.2)

0.96 [0.22, 4.14]

Age

59.8 ± 12.6

59.0 ± 14.2

1.00 [0.96, 1.04]

60.2 ± 11.9

60.1 ± 15.5

1.00 [0.96,1.03]

58.6 ± 12.9

60.4 ± 13.5

0.94 [0.88, 1.00]

Education (in years)

14.6 ± 3.4

15.2 ± 3.4

1.01 [0.86, 1.14]

14.0 ± 3.2

15.3 ± 3.4

0.90 [0.79, 1.03]

13.5 ± 2.8

15.6 ± 3.3

0.69 [0.54, 0.88]

Stage 0 (in situ)

11.0 (12.9)

11.0 (18.3)

REF

6.0 (10.0)

13.0 (18.6)

REF

1.0 (2.9)

13.0 (19.4)

REF

1

44.0 (51.8)

34.0 (56.7)

0.51 [0.12, 2.08]

28.0 (46.7)

43.0 (61.4)

0.59 [0.15, 2.30]

18.0 (52.9)

39.0 (58.2)

NE

2

20.0 (23.5)

13.0 (21.7)

0.37 [0.08, 1.82]

20.0 (33.3)

12.0 (17.1)

1.85 [0.42, 8.20]

12.0 (35.3)

13.0 (19.4)

NE

3

5.0 (5.9)

2.0 (3.3)

0.78 [0.08, 7.72]

2.0 (3.3)

2.0 (2.9)

1.55 [0.13, 18.39]

1.0 (2.9)

2.0 (3.0)

NE

4

5.0 (5.9)

0.0 (0.0)

NE

4.0 (6.7)

0.0 (0.0)

NE

2.0 (5.9)

0.00 (0.00)

NE

Melanoma knowledge

0.8 ± 0.2

0.8 ± 0.2

0.36 [0.03, 4.93]

0.8 ± 0.2

0.8 ± 0.2

0.72 [0.08, 6.69]

0.8 ± 0.2

0.8 ± 0.2

3.59 [0.11, 118.01]

SSE intentions

4.8 ± 0.6

3.8 ± 1.0

4.48 [2.17, 9.23]

4.7 ± 0.7

4.1 ± 1.0

1.52 [0.81, 2.88]

4.9 ± 0.4

4.2 ± 1.0

4.26 [0.96, 18.88]

SSE self-efficacy

2.2 ± 0.4

1.8 ± 0.5

5.31 [1.53, 18.40]

2.2 ± 0.5

1.9 ± 0.5

2.95 [1.03, 8.43]

2.3 ± 0.4

1.9 ± 0.5

5.04 [1.11, 22.83]

SCI

2.0 ± 0.7

2.0 ± 0.8

0.80 [0.39, 1.62]

2.1 ± 0.8

1.9 ± 0.7

1.92 [0.95, 3.87]

2.2 ± 0.8

1.9 ± 0.7

3.03 [1.00, 9.24]

PHQ4

0.5 ± 0.8

0.6 ± 0.9

1.09 [0.51, 2.33]

0.4 ± 0.6

0.6 ± 0.9

0.75 [0.35, 1.59]

0.4 ± 0.7

0.5 ± 0.9

0.42 [0.11, 1.56]

FKV-2

3.7 ± 0.5

3.5 ± 0.4

2.54 [0.80, 8.03]

3.7 ± 0.5

3.5 ± 0.4

4.76 [1.48, 15.29]

3.8 ± 0.3

3.6 ± 0.4

3.06 [0.55, 17.05]

heiQ

2.4 ± 0.5

2.3 ± 0.6

0.55 [0.19, 1.54]

2.4 ± 0.5

2.3 ± 0.6

1.02 [0.38, 2.75]

2.4 ± 0.5

2.4 ± 0.6

1.00 [0.24, 4.22]

  1. Note. Statistics for the SSE endorsed/not endorsed were presented as n (%) or M ± SD, where M mean and SD standard deviation, NE Not estimable
  2. *Stepwise regressions adjusted for all of the study measures
  3. SSE Skin self-examination, SCI Skin Cancer Index, assessing distress, PHQ-4 Patient Health Questionnaire-4, assessing depression and anxiety, FKV-2 2 items of the Freiburg Questionnaire of Coping with Illness, assessing reliance on medical advice, heiQ The Health Education Impact Questionnaire, assessing constructive attitudes about health